Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets

November 12, 2025

Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets

Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology, leveraging its expertise in immune system regulation.Recent Phase 2 results for Atopic Dermatitis met endpoints, validating NKTR's approach and

by admin

Healthcare Stocks

Stock Market

October 27, 2025

GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth

GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings.Key metrics for WGS include test volume growth and reimbursement

by admin

Jonathan Kitchen via Getty Images via Seeking Alpha

Biotechnology Stocks

Stock Market

October 21, 2025

Cidara Therapeutics: A Potential Blockbuster In Flu Prevention

Cidara’s CD388 is a novel flu prophylactic designed for universal prevention of seasonal and pandemic influenza through a single dose, with the potential to be the new standard of care.Phase

by admin

Healthcare Stocks

Stock Market

July 31, 2025

GeneDx Surges Past Q2 Expectations,Sets Up for Strong Year-End Growth

GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%.Revenue growth is driven by higher testing volumes, improved reimbursement rates, and a

by admin

Healthcare Stocks

Stock Market

May 20, 2025

GeneDx: Strong Fundamentals Intact As
Market Misreads Test Volume Dip

GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance.The test volume dip is attributable to seasonality, adverse weather, and one fewer business day, not

by admin

Healthcare Stocks

Stock Market

October 21, 2024

GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists

GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing.The company’s second-quarter performance exceeded expectations, driven by

by admin

Healthcare Stocks

Stock Market

July 22, 2024

Healthcare 2024 Second Half Outlook

The S&P Healthcare Index rose 6% in the first half of the year, while the Prudent Healthcare model portfolio gained 25%.While the healthcare index underperformed the broader market, there are

by admin

Biotechnology Stocks

Stock Market

July 9, 2024

Biotech Stocks 2024 Second Half Outlook
Buy Biotechs

Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022.Biotech valuations are closely tied to the Fed's interest

by admin

Biotechnology Stocks

Stock Market

June 24, 2024

Nuvalent: Making Precise Progress
In Its Oncology Pipeline

Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer.NVL-520 targets ROS1-positive cancer and addresses treatment resistance, kinase mutations, and CNS-related adverse events,

by admin

Biotechnology Stocks

Stock Market

May 30, 2023

Iveric bio, Still A 5+% Opportunity

Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc.Iveric bio, Inc. stock trades at a discount of over 5% for an

by admin

Biotechnology Stocks

Stock Market

April 24, 2023

Biotech Stocks Second Quarter Outlook

Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.Biotech deal-making has been increasing,

by admin

Biotechnology Stocks

Stock Market

March 13, 2023

Biotechs Reel From Bank Collapse, But Not All May Be Bad

The collapse of Silicon Valley Bank led to a market-wide selloff and caused significant volatility in biotech and technology stocks.Regulators are expected to take swift action this week to contain

January 23, 2023

Healthcare Outlook 2023

Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500.When the end to restrictive policy is in sight, then the sector is likely to

by admin

Biotechnology Stocks

Stock Market

January 9, 2023

Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish

Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half.Biotechnology should be favorably positioned relative to the market if the economy

by admin